trending Market Intelligence /marketintelligence/en/news-insights/trending/iCHPvWRs_S-74E01KPmy5Q2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Dermira to develop Roche drug for skin condition

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Dermira to develop Roche drug for skin condition

Dermira Inc. secured the worldwide rights to develop F. Hoffmann-La Roche Ltd. and Genentech Inc.'s lebrikizumab in treating atopic dermatitis, a skin condition.

Dermira can also commercialize the drug in other indications except for interstitial lung diseases whose rights remain with Hoffmann-La Roche and Genentech. The two Roche Holding AG units can further continue to develop the drug for internal research and in vitro diagnostic purposes.

Dermira will make an initial payment of $80 million and a further $55 million in 2018. Another $40 million will be paid once Dermira initiates the first phase 3 study of lebrikizumab and up to $210 million once certain milestones are met.

Finally, up to $1.03 billion will be paid once the drug achieves pre-specified sales targets for indications other than interstitial lung disease. The amount is separate from the royalties that will be paid on the sales of the drug.

Dermira plans to initiate a phase 2b dose-ranging study assessing lebrikizumab in adult patients with moderate-to-severe atopic dermatitis in the first quarter of 2018. The objective will be to optimize the dose of lebrikizumab for the design of a phase 3 program.

Dermira anticipates that it will spend approximately $200 million to obtain the top-line results for the phase 2b study.

Leerink Partners LLC acted as the financial adviser to Dermira, with King & Spalding LLP and Fenwick & West LLP acting as legal counsel.